Article Contents ::
- 1 The Brand Name NODICT Has Generic Salt :: Naltrexone
- 2 NODICT Is From Company Synergy Priced :: Rs. 400
- 3 NODICT have Naltrexone is comes under Sub class #N,A of Main Class #N,A
- 4 Main Medicine Class:: #N,A Sub Medicine Class :: #N,A
- 5 Disclaimer ::
The Brand Name NODICT Has Generic Salt :: Naltrexone
NODICT Is From Company Synergy Priced :: Rs. 400
NODICT have Naltrexone is comes under Sub class #N,A of Main Class #N,A
Main Medicine Class:: #N,A Sub Medicine Class :: #N,A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Opioid dependence, Alcohol dependence
Drug Dose ::
Adult: PO Opioid dependence Initial: 25 mg, then up to 50 mg/day if no withdrawal signs. Maintenance: 350 mg/wk given as 50 mg/day or divided in 3 doses (given on 3 days of the wk) for improved compliance. Adjunct in alcohol dependence 50 mg/day.
Patients concurrently dependent on opioids; acute hepatitis or hepatic failure; acute opioid withdrawal; patients on therapeutic opioid analgesics.
Drug Precautions ::
Hepatic or renal impairment. Monitor LFTs regularly. Patients should be opioid-free for at least 7-10 days prior to initiating naltrexone therapy. Strictly warn patients against the use of opioids while on naltrexone. Monitor for inj-site reactions. Pregnancy, lactation. History of bleeding disorders (including thrombocytopenia).
Drug Side Effects ::
Abdominal pain, nausea, vomiting; anxiety, insomnia, lethargy, headache, musculoskeletal pain; anorexia, diarrhoea, constipation; increased thirst; chest pain; chills, dizziness; sexual dysfunction; rash, liver function abnormalities and reversible idiopathic thrombocytopenia. Inj-site reactions.
Pregnancy category ::
Drug Mode of Action ::
Naltrexone acts as a competitive antagonist at opioid receptor sites. It blocks the action of opioids and precipitates withdrawal symptoms in opioid-dependent individuals.
Drug Interactions ::
May reduce effects of opiate-containing preparations e.g. those used for cough and cold, diarrhoea and pain. Increased or decreased serum levels with drugs that alter hepatic metabolism. Potentially increased hepatotoxic effects with disulfiram. Increased risk of naltrexone-induced lethargy and somnolence with thioridazine. May increase insulin requirements.